灯盏花、丹参液在体外对血小板活化抑制作用的研究  

Study on the action of breviscapus and saliva for in vitro inhibiting platelet activation

作　　者：陈辉[1] 邵跃斌[1] 黎庆梅[1] 段朝辉[2] 

机构地区：[1]暨南大学第四附属医院/广州市红十字会医院,510220 [2]中山大学孙逸仙纪念医院检验科,广州510080

出　　处：《国际医药卫生导报》2009年第21期1-5,共5页International Medicine and Health Guidance News

基　　金：广东省中医药局建设中医强省科研课题(20060053)

摘　　要：目的通过对灯盏花素、丹参在体外对血小板活化抑制作用观察,分析血小板相关活化指标的变化情况,为中医优选活血化瘀药物提供客观理论依据。方法用三色流式细胞术法分析灯盏花素、丹参在体外对血小板活化指标血小板膜表面纤维蛋白原受体(PAC-1)和P-选择素(CD62P)抑制的变化。结果灯盏花素、丹参对ADP活化的血小板膜表面纤维蛋白原受体(PAC-1)和血小板内P-选择素(CD62P)表达都有抑制作用,并且随着药物浓度的增加,抑制作用增强;丹参能显著抑制PAC-1和CD62P两者的表达;灯盏花素抑制PAC-1表达的作用显著,但对CD62P表达的抑制较小。结论与灯盏花素相比,丹参是一种较强的抗血小板活化药物,既可抑制PAC-1的表达而降低血小板的聚集性,又可抑制血小板的释放而降低其促凝血活性,在血栓性疾病的防治中有重要作用。Objective To study the action of breviseapus and saliva in inhibiting platelet activation in vitro and to provide more scientific evidence and theoretical basic for the treatment of blood stasis syndrome. Method Two kinds of anti-platelet drugs and controls, which inhibited the expression of fibrinogen receptor （PAC-1） and P-2seleetin （CD62P） on activated platelets surface in vitro , were analyzed by tri-color floweytometry.Results Both of two kinds of anti-platelet drugs can inhibite the expression of PAC-1 and CD62P on ADPaetivating platelet membrane surface. With the increase of the concentration of drug, the ability of inhibiting become enhanced. Saliva could inhibit the expression of FIB-1 and CD62P of the platelets markedly, breviseapus could inhibit the PAC-1 expression markedly , but CD62P indistinctly. Conclusion Saliva is a strong anti-platelet drug as compared with breviseapus. It could not only inhibit PAC-1 expression of activated platelets, which can prevent platelet aggregation, but also decrease the release reaction and proeoagnlative activities of activated platelets. Saliva will play an important role in treatment of thrombus in the feature.

关 键 词：血小板活化 流式细胞术 丹参 灯盏花素 

分 类 号：R285[医药卫生—中药学]